Huang Jianxiang, Zou Fuxian, Zhu Jianhong, Wu Zexin, Lin Chao, Wei Peipeng, Su Huamei, Li Meisang, Huang Qiuping, Cai Jianfeng
Department of Pharmacy, Quanzhou Orthopedic Traumatological Hospital of Fujian University of Traditional Chinese Medicine, Quanzhou, PR China.
Department of Pharmacy, Sun-Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China.
Expert Opin Drug Saf. 2024 Aug 27:1-6. doi: 10.1080/14740338.2024.2396390.
Previous studies have documented an increased risk of pulmonary embolism (PE) in patients with schizophrenia taking antipsychotics (APs). However, specific data from real-world studies remain limited. This study aims to investigate the potential relationship between APs and PE.
In the Food and Drug Administration Adverse Event Reporting System (FAERS), from the first quarter of 2018 to the first quarter of 2023, all PE cases suspected of being induced by APs were collected for disproportionality analysis, and the reporting odds ratio (ROR) was used to evaluate associations. Mortality, life-threatening events, and hospitalizations were also analyzed for each APs.
A total of 1,676 cases of PE related to APs were included. APs were significantly associated with PE (ROR 2.00, 1.91-2.10), including chlorpromazine ( = 41), haloperidol ( = 164), loxapine ( = 37), olanzapine ( = 461), paliperidone ( = 161), quetiapine ( = 526), risperidone ( = 274), aripiprazole ( = 254), and clozapine ( = 234). The median onset time of PE was 29 days. Among all cases, 347 (20.7%) resulted in death, with haloperidol (53.2%) having a higher mortality rate than other APs.
APs may increase the risk of PE in patients with schizophrenia.
既往研究已证实，服用抗精神病药物（APs）的精神分裂症患者发生肺栓塞（PE）的风险增加。然而，来自真实世界研究的具体数据仍然有限。本研究旨在调查APs与PE之间的潜在关系。
在食品药品监督管理局不良事件报告系统（FAERS）中，收集2018年第一季度至2023年第一季度所有疑似由APs诱发的PE病例进行不成比例分析，并使用报告比值比（ROR）评估关联性。还对每种APs的死亡率、危及生命事件和住院情况进行了分析。
共纳入1676例与APs相关的PE病例。APs与PE显著相关（ROR 2.00，1.91 - 2.10），包括氯丙嗪（= 41）、氟哌啶醇（= 164）、洛沙平（= 37）、奥氮平（= 461）、帕利哌酮（= 161）、喹硫平（= 526）、利培酮（= 274）、阿立哌唑（= 254）和氯氮平（= 234）。PE的中位发病时间为29天。在所有病例中，347例（20.7%）导致死亡，氟哌啶醇（53.2%）的死亡率高于其他APs。
APs可能会增加精神分裂症患者发生PE的风险。
